SLAMF1 Antibody

What is SLAMF1 and what cellular populations express it?

SLAMF1, also known as CD150 or Signaling Lymphocytic Activation Molecule Family Member 1, is a self-ligand receptor belonging to the SLAM family. It is predominantly expressed on lymphocytes and functions as a costimulatory molecule that initiates signal transduction networks in various immune cells . SLAMF1 expression is regulated by different stimuli, with particularly strong upregulation observed following bacterial stimulation (such as M. tuberculosis) and IFN-γ exposure . In humans, SLAMF1 shows high expression in the thymus, spleen, and bone marrow . At the cellular level, resting macrophages display minimal surface SLAMF1, with the majority located in the endocytic recycling compartment (ERC), while activated B and T cells significantly upregulate SLAMF1 expression .

What are the structural characteristics of SLAMF1?

SLAMF1 is a type I glycoprotein belonging to the SLAM subfamily of the CD2-like family of proteins . The human version has a canonical amino acid length of 335 residues and a protein mass of approximately 37.2 kilodaltons, with at least four identified isoforms . Its structure includes an extracellular domain that mediates homophilic interactions, a transmembrane region, and a cytoplasmic tail containing tyrosine-based motifs that serve as docking sites for adapter proteins such as SAP (SH2D1A) and EAT-2 (SH2D1B) .

How does SLAMF1 signaling function in immune responses?

SLAMF1 operates through two primary signaling modes: one dependent on SH2D1A (and possibly SH2D1B) adapter proteins, and another involving protein-tyrosine phosphatase (PTPN11)-dependent signal transduction . In T lymphocytes, SLAMF1 promotes IL-2-independent proliferation during immune responses and induces IFN-γ production . When activated, SLAMF1 can recruit the kinase FYN, which phosphorylates and further activates SLAMF1-mediated signaling pathways . Importantly, the signaling outcomes differ between cell types - SLAMF1-induced signal-transduction events in T-lymphocytes are distinct from those in B-cells .

What applications are SLAMF1 antibodies suitable for in research?

SLAMF1 antibodies can be utilized in multiple applications depending on their specific characteristics:

For optimal results, select antibodies validated for specific applications and species reactivity .

How should researchers select appropriate SLAMF1 antibodies for specific experimental purposes?

Selection of SLAMF1 antibodies should be guided by multiple factors:

• Target epitope consideration: Choose antibodies recognizing specific regions (e.g., extracellular domain for flow cytometry, C-terminal for total protein detection) .

• Species reactivity: Verify compatibility with your experimental model. Some antibodies are human-specific, while others recognize multiple species (human/rat/mouse) .

• Clonality assessment: Monoclonal antibodies offer high specificity for particular epitopes (e.g., SLAM-4 clone recognizes an extracellular epitope of CD150), while polyclonal antibodies provide broader epitope recognition .

• Application compatibility: Ensure the selected antibody has been validated for your specific application. For example, the SLAM-4 clone is validated for flow cytometry, immunoprecipitation, and immunocytochemistry, but not for Western blotting .

• Conjugation requirements: For multicolor flow cytometry, select appropriately conjugated antibodies (FITC, APC) to avoid fluorophore conflicts .

What are the best practices for validating SLAMF1 antibody specificity?

Thorough validation of SLAMF1 antibodies is essential to ensure reliable results:

• Positive and negative control samples: Use cells known to express high levels of SLAMF1 (e.g., activated lymphocytes) as positive controls and cells lacking SLAMF1 expression as negative controls .

• Antibody titration: Perform detailed titration experiments to determine optimal concentrations that maximize signal-to-noise ratio.

• Knockdown/knockout verification: Where possible, confirm specificity using SLAMF1 siRNA knockdown or CRISF/Cas9 knockout models. In studies with THP-1 cells, SLAMF1-specific siRNA resulted in consistent reduction of SLAMF1 expression, confirming antibody specificity .

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other SLAM family members, particularly when using polyclonal antibodies.

• Blocking experiments: Perform peptide blocking experiments using the immunizing peptide to confirm binding specificity, particularly for antibodies generated against synthetic peptides .

How does SLAMF1 modulate T cell-B cell interactions in normal and autoimmune contexts?

Research using SLAMF1 monoclonal antibodies has revealed that SLAMF1 ligation reduces T-B conjugate formation, decreases IL-6 production by B cells, and diminishes IL-21 and IL-17A production by T cells in peripheral blood cultures from both healthy controls and SLE patients . The antibody directly affects B cell function by reducing IL-6 and immunoglobulin production in vitro, while having minimal direct effects on isolated T cells .

These findings suggest that therapeutic targeting of SLAMF1 could potentially disrupt pathological T-B cell interactions in autoimmune diseases, offering a novel approach for treating conditions like SLE .

What is SLAMF1's role in bacterial pathogen recognition and clearance?

SLAMF1 serves a critical function in bacterial recognition and clearance through several mechanisms:

• Bacterial uptake facilitation: SLAMF1 enhances the internalization of Mycobacterium tuberculosis by human macrophages when stimulated with an agonistic antibody . This function appears to be mediated through direct interaction between SLAMF1 and the bacteria .

• Endolysosomal maturation: SLAMF1 colocalizes with bacterial phagosomes and endolysosomal markers (EEA1 and LAMP2), suggesting its involvement in phagosomal maturation processes necessary for bacterial killing .

• TLR4 signaling regulation: In human macrophages, SLAMF1 acts as a critical regulator of TLR4-mediated signaling from phagosomes by interacting with the Toll receptor-associated molecule (TRAM) . This interaction is enhanced upon LPS stimulation and is specific to TRAM, not occurring with MyD88 .

• Type I interferon production: SLAMF1 is required for TLR4-mediated induction of interferon β (IFNβ) in response to Gram-negative bacteria . SLAMF1 silencing in macrophages causes consistent reduction in LPS-mediated IFNβ responses .

Notably, SLAMF1's role in bacterial responses shows species-specific differences, with the SLAMF1-TRAM interaction observed in human but not mouse proteins .

What is the relationship between SLAMF1 and protective immunity in infectious disease models?

SLAMF1 plays complex roles in protective immunity against infections:

• Fungal infection resistance: SLAMF1 is indispensable for host resistance to primary and vaccine-induced protection against fungal infection . Unvaccinated and vaccinated SLAMF1-deficient mice fail to control fungal infection despite developing normal T cell responses .

• T cell development independence: Intrinsic and extrinsic SLAMF1 signaling is dispensable for the development of antifungal Th1 and Th17 cells, which are required for vaccine-induced immunity . SLAMF1-/- T cells showed enhanced expansion but increased contraction compared to wild-type cells in adoptive transfer experiments .

• Inflammatory regulation: Failed accumulation of antigen-specific T cells in the lungs of vaccinated SLAMF1-/- mice results from uncontrolled early infection and inflammation, revealing SLAMF1's role in innate host immunity .

• Cytokine production: Splenocytes from vaccinated SLAMF1-/- mice produce less IL-17 and IFN-γ after stimulation with fungal antigen compared to wild-type mice, indicating SLAMF1's contribution to protective cytokine responses .

These findings highlight SLAMF1's multifaceted roles in infection control, particularly in regulating early inflammatory responses rather than directly affecting T cell development.

How can researchers design experiments to study SLAMF1-mediated cellular interactions?

To effectively study SLAMF1-mediated cellular interactions, consider the following experimental approaches:

• T cell-B cell co-culture systems: Design co-culture experiments with isolated B cells (e.g., stimulated with anti-IgM F(ab')2 fragments) and autologous T cells (stimulated with CD3/CD28) in the presence or absence of SLAMF1 monoclonal antibodies . Key readouts include:

  • Conjugate formation assessment by flow cytometry

  • Cytokine production (IL-6, IL-21, IL-17A) measurement by flow cytometry and qPCR

  • Plasmablast formation quantification

  • Immunoglobulin and autoantibody production determination by ELISA

• SLAMF1 trafficking studies: To investigate SLAMF1 trafficking during cellular interactions:

  • Use confocal microscopy with fluorescently-labeled anti-SLAMF1 antibodies

  • Co-stain with markers for different cellular compartments (GM130 for Golgi, Rab11a for recycling endosomes, EEA1 for early endosomes, LAMP1 for late endosomes)

  • Perform live-cell imaging to track SLAMF1 movement during bacterial phagocytosis or cell-cell interactions

• Protein-protein interaction analysis:

  • Conduct endogenous immunoprecipitation experiments using anti-SLAMF1 and anti-partner protein (e.g., anti-TRAM) antibodies

  • Confirm specificity using appropriate controls (e.g., MyD88 for TRAM interactions)

  • Use techniques like proximity ligation assay to visualize protein interactions in intact cells

• Functional modulation experiments:

  • Compare agonistic versus antagonistic anti-SLAMF1 antibodies to distinguish between blocking and stimulating effects

  • Include F(ab')2 fragments to eliminate Fc receptor-mediated effects

  • Design time-course experiments to capture both early and late effects of SLAMF1 engagement

What controls should be included when using SLAMF1 antibodies in functional studies?

Robust experimental design requires appropriate controls when using SLAMF1 antibodies:

• Antibody-specific controls:

  • Isotype-matched control antibodies to account for non-specific effects

  • F(ab')2 fragments versus whole antibodies to distinguish Fc receptor-mediated effects

  • Concentration-matched control antibodies targeting irrelevant proteins

• Cellular controls:

  • SLAMF1-knockdown or knockout cells generated using siRNA or CRISPR/Cas9

  • Cells with naturally different SLAMF1 expression levels (e.g., resting versus activated lymphocytes)

  • Cells from different species when studying species-specific effects (human versus mouse)

• Experimental condition controls:

  • Unstimulated versus stimulated conditions (e.g., with/without LPS, IFN-γ, or bacterial stimulation)

  • Time-course analyses to capture transient versus sustained effects

  • Dose-response experiments with varying antibody concentrations

• Technical controls:

  • Blocking peptides corresponding to the antibody epitope to confirm specificity

  • Secondary antibody-only controls to assess background signal

  • Pre-immune serum controls when using polyclonal antibodies

How should researchers interpret contradictory findings regarding SLAMF1 function across different experimental systems?

When encountering contradictory findings about SLAMF1 function, consider these factors:

• Species-specific differences: The interaction between SLAMF1 and TRAM is observed in human but not mouse proteins, highlighting critical species-specific differences . This explains why studies in mouse models might yield different results than human cell systems.

• Cell type-specific effects: SLAMF1 signaling differs between T cells and B cells . In T cells, SLAMF1 engagement promotes proliferation and IFN-γ production, while in B cells, its effects on activation can vary. Studies using mixed populations versus purified cell subsets may yield different results.

• Context-dependent functionality:

  • In bacterial recognition, SLAMF1 promotes bacterial uptake and clearance

  • In T-B interactions, SLAMF1 antibody reduces conjugate formation and cytokine production

  • In fungal immunity, SLAMF1 is essential for protection despite being dispensable for T cell development

• Antibody characteristics: Different antibody clones can yield contradictory results depending on:

  • Epitope specificity (extracellular versus intracellular domains)

  • Functional effects (agonistic versus antagonistic)

  • Isotype and Fc-mediated effects

When interpreting contradictory findings, carefully consider the experimental system, cell types, species, stimulation conditions, and antibody properties to develop a more nuanced understanding of SLAMF1's context-dependent functions.

What methodological approaches can resolve differences between in vitro and in vivo findings on SLAMF1 function?

To reconcile differences between in vitro and in vivo findings regarding SLAMF1 function:

• Use ex vivo analysis of primary cells:

  • Isolate cells from in vivo models (e.g., SLAMF1-/- mice) for detailed ex vivo functional studies

  • Compare with in vitro cultured cells to identify culture-induced artifacts

  • Analyze cells from different tissue compartments to understand site-specific functions

• Employ adoptive transfer approaches:

  • Transfer SLAMF1-sufficient or -deficient cells into appropriate recipients to study cell-intrinsic versus -extrinsic effects

  • Use mixed bone marrow chimeras to evaluate competitive fitness of SLAMF1-sufficient versus -deficient cells in the same in vivo environment

  • Combine with reporter systems to track cell fate and function

• Implement tissue-specific or conditional knockout models:

  • Use Cre-lox systems to delete SLAMF1 in specific cell types or at specific times

  • Compare with germline knockouts to distinguish developmental versus functional roles

  • Employ inducible systems to avoid developmental compensation

• Apply advanced imaging techniques:

  • Use intravital microscopy to visualize SLAMF1-mediated interactions in live animals

  • Combine with reporter systems to track cellular activation states

  • Correlate imaging findings with functional readouts from the same animals

• Conduct parallel human studies:

  • Analyze SLAMF1 expression and function in relevant human samples (e.g., pleural effusions from tuberculosis patients)

  • Compare findings from human cells with mouse models to identify species-specific differences

  • Use humanized mouse models to bridge the gap between human and mouse studies

By systematically applying these approaches, researchers can develop a more comprehensive understanding of SLAMF1's functions across different experimental systems and better translate findings between in vitro and in vivo contexts.

How might SLAMF1-targeted approaches be developed for immunotherapy?

Based on SLAMF1's roles in immune regulation, several potential immunotherapeutic strategies emerge:

• Autoimmune disease applications:

  • SLAMF1 antibodies could inhibit T-B cell interaction and suppress B cell cytokine production and differentiation, representing a potential therapeutic tool for SLE patients

  • Targeting SLAMF1 might reduce plasmablast formation and autoantibody production in antibody-mediated autoimmune conditions

• Infectious disease interventions:

  • Agonistic SLAMF1 antibodies could enhance bacterial uptake and clearance in infections like tuberculosis by promoting phagolysosomal maturation

  • SLAMF1-targeted approaches might boost protective immunity in fungal infections by enhancing innate immune responses

• Cancer immunotherapy potential:

  • Some members of the SLAM family act as inhibitory immune checkpoints, suggesting SLAMF1 might be a novel therapeutic target to boost antitumoral immunity

  • SLAMF1 antibodies could potentially modulate tumor-associated macrophage function in the tumor microenvironment

When developing such approaches, researchers must carefully consider potential on-target off-tumor effects, as SLAMF1 has widespread expression on immune cells and plays crucial roles in normal immune function .

What experimental evidence supports species-specific differences in SLAMF1 function?

Several lines of evidence highlight important species-specific differences in SLAMF1 function:

• Protein-protein interactions: The SLAMF1-TRAM interaction occurs with human but not mouse proteins, as demonstrated through endogenous immunoprecipitation experiments . The key interaction domains were identified as amino acids 68-95 of TRAM and the 15 C-terminal amino acids of SLAMF1 .

• Signaling pathway differences: In human macrophages, SLAMF1 regulates TLR4-TRAM-TRIF signaling, with SLAMF1 silencing causing consistent reduction in LPS-mediated IFNβ responses . These findings may not translate directly to mouse models due to the species-specific protein interactions.

• Functional outcomes: While mouse SLAMF1 positively regulates NOX2 activity by forming a complex with beclin-1-Vps34-Vps15-UVRAG, human SLAMF1 has distinct functions in regulating TRAM trafficking from the endocytic recycling compartment to bacterial phagosomes .

• Research implications: These species differences necessitate caution when extrapolating findings between mouse models and human systems, especially when studying innate immune signaling pathways and host-pathogen interactions .